In addition, both GLP1‐based therapy and SGLT2 inhibitors may have a more pronounced effect on the pathophysiological mechanisms involved in MASLD/MASH like the positive effects on body weight and the anti‐inflammatory effects. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.